AU
UK
CA
NZ
IND
US
Last update at 2026-06-23T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update
Tue 05 Aug 25, 08:01 PMEuropean Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading
Fri 18 Jul 25, 03:09 PMEuropean Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
Wed 16 Jul 25, 03:24 PMHigh Growth Tech Stocks in Europe with Promising Potential
Fri 11 Jul 25, 05:38 AMEuropean Equities Traded in the US as American Depositary Receipts Advance in Tuesday Trading
Tue 08 Jul 25, 03:08 PMEuropean Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
Tue 24 Jun 25, 03:08 PM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 614.85M | 444.00M | 224.02M | 361.26M | 350.45M |
| Minority interest | -98.00000M | -55.88600M | -114.90200M | -62.86700M | -82.52400M |
| Net income | 401.74M | 156.92M | 59.31M | 208.28M | 182.80M |
| Selling general administrative | 1063.00M | 1144.01M | 1259.53M | 1190.42M | 1061.51M |
| Selling and marketing expenses | - | - | 107.14M | - | - |
| Gross profit | 2858.44M | 2794.54M | 2494.57M | 2231.53M | 1962.60M |
| Reconciled depreciation | 450.00M | 437.90M | 441.92M | 407.86M | 359.77M |
| Ebit | - | 1046.57M | 735.57M | 704.16M | 595.62M |
| Ebitda | 1250.03M | 1484.46M | 1182.00M | 1112.03M | 955.39M |
| Depreciation and amortization | - | 437.90M | 446.42M | 407.86M | 359.77M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 1250.03M | 1192.02M | 799.40M | 805.68M | 595.06M |
| Other operating expenses | 6271.35M | 6020.37M | 5792.58M | 5361.77M | 4370.61M |
| Interest expense | 628.00M | 739.94M | 516.06M | 362.63M | 233.81M |
| Tax provision | 115.00M | 231.19M | 27.21M | 90.11M | 85.13M |
| Interest income | 34.00M | 44.42M | 62.33M | 33.86M | 11.55M |
| Net interest income | -605.00000M | -701.12400M | -574.13600M | -462.66500M | -266.44300M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 114.57M | 231.19M | 43.35M | 90.11M | 85.13M |
| Total revenue | 7521.39M | 7212.38M | 6591.98M | 6063.97M | 4933.12M |
| Total operating expenses | 1608.41M | 1602.52M | 1695.17M | 1529.33M | 1400.09M |
| Cost of revenue | 4662.94M | 4417.84M | 4097.41M | 3832.44M | 2970.52M |
| Total other income expense net | -635.18201M | -748.01900M | -575.38000M | 121.72M | 54.39M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 500.00M | 212.81M | 138.29M | 271.15M | 265.33M |
| Net income applicable to common shares | - | - | - | 208.28M | 182.80M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 19703.98M | 21405.24M | 21441.05M | 21533.98M | 19233.83M |
| Intangible assets | 2726.98M | 2926.13M | 1207.55M | 2949.15M | 1636.95M |
| Earning assets | - | - | - | - | - |
| Other current assets | 99.86M | 87.17M | 1653.72M | 81.81M | 64.08M |
| Total liab | 12102.96M | 12798.22M | 13468.57M | 13076.43M | 11086.80M |
| Total stockholder equity | 5269.79M | 5883.73M | 5827.17M | 6129.94M | 6096.64M |
| Deferred long term liab | - | - | - | 1622.64M | 633.24M |
| Other current liab | 791.36M | 508.33M | 445.13M | 504.82M | 407.60M |
| Common stock | 119.56M | 119.60M | 119.60M | 119.60M | 119.60M |
| Capital stock | 120.00M | 119.60M | 119.60M | 119.60M | 1030.33M |
| Retained earnings | 300.00M | 156.92M | 42.32M | 208.28M | 182.80M |
| Other liab | - | - | - | 2051.73M | 682.36M |
| Good will | 6830.44M | 7403.06M | 6802.13M | 7011.91M | 6228.90M |
| Other assets | - | - | -13.61600M | 1930.41M | 882.61M |
| Cash | 825.18M | 979.78M | 529.58M | 547.98M | 655.49M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 2017.90M | 2156.15M | 2325.44M | 1955.85M | 3474.31M |
| Current deferred revenue | - | 70.86M | 39.19M | 37.83M | 43.54M |
| Net debt | 8814.33M | 9105.84M | 10443.38M | 9202.15M | 8668.81M |
| Short term debt | 385.86M | 639.66M | 1013.48M | 681.27M | 2394.18M |
| Short long term debt | 410.00M | 523.13M | 790.81M | 578.92M | 2345.61M |
| Short long term debt total | 9639.51M | 10085.62M | 10972.95M | 9750.12M | 9324.31M |
| Other stockholder equity | 5264.18M | 776.28M | 1216.77M | 748.51M | 746.54M |
| Property plant equipment | - | - | - | 4168.49M | 3343.15M |
| Total current assets | 5070.88M | 5727.54M | 6451.90M | 4653.59M | 5510.28M |
| Long term investments | 460.00M | 528.97M | 565.11M | 2548.89M | 2359.97M |
| Net tangible assets | - | - | - | -2208.47700M | -1135.96800M |
| Short term investments | 23.00M | 21.18M | 116.14M | 43.26M | 2029.11M |
| Net receivables | 851.22M | 1079.32M | 692.86M | 754.82M | 495.48M |
| Long term debt | 8074.00M | 8421.11M | 8215.30M | 8154.26M | 6104.97M |
| Inventory | 3294.62M | 3560.10M | 3459.28M | 3201.36M | 2259.35M |
| Accounts payable | 840.69M | 852.30M | 813.11M | 731.92M | 628.99M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -113.94531M | 4830.92M | 4448.47M | 5053.55M | 5047.70M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1347.54M | 167.72M | 2222.01M | 54.06M | 4.14M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 14633.09M | 15677.70M | 14989.15M | 16880.39M | 13723.56M |
| Capital lease obligations | 1082.00M | 1141.38M | 1111.33M | 1016.94M | 873.72M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -52.00000M | 886.67M | -397.63600M | -1978.82300M | 9.82M |
| Change to liabilities | - | - | - | 80.21M | 40.45M |
| Total cashflows from investing activities | -578.78314M | 886.67M | -397.63600M | -1978.82300M | -29.39300M |
| Net borrowings | -119.00000M | -111.48800M | -116.39400M | -177.37200M | 1878.52M |
| Total cash from financing activities | -528.80187M | -1358.71400M | 186.04M | -173.49300M | 1472.92M |
| Change to operating activities | - | - | - | -9.01000M | -7.07500M |
| Net income | 401.85M | 444.00M | 59.31M | 361.26M | 350.45M |
| Change in cash | -38.56938M | 450.20M | -18.40200M | -2127.63200M | 2095.96M |
| Begin period cash flow | 863.26M | 529.58M | 547.98M | 2675.61M | 579.65M |
| End period cash flow | 824.69M | 979.78M | 529.58M | 547.98M | 2675.61M |
| Total cash from operating activities | 1046.61M | 902.17M | 208.28M | -10.86700M | 596.98M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 449.83M | 437.90M | 441.92M | 407.86M | 359.77M |
| Other cashflows from investing activities | - | 1448.93M | -80.45200M | - | - |
| Dividends paid | 127.95M | 0.96M | 0.00000M | -0.59200M | -258.94600M |
| Change to inventory | -96.96367M | 25.82M | -427.09500M | -600.24500M | -157.47400M |
| Change to account receivables | -31.98801M | -41.88300M | -53.14000M | -80.17000M | -16.80600M |
| Sale purchase of stock | -128.95168M | 0.00000M | 0.00000M | -3.45900M | -125.70300M |
| Other cashflows from financing activities | -81.96929M | -1246.26400M | 5.47M | -65.15500M | 1940.26M |
| Change to netincome | - | - | - | -17.79100M | 195.31M |
| Capital expenditures | 264.90M | 371.37M | 295.42M | 375.56M | 315.09M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -24.99064M | 22.38M | -362.84300M | -609.21900M | -140.90800M |
| Stock based compensation | - | - | - | - | - |
| Other non cash items | 219.92M | -2.10100M | 69.89M | -170.76900M | 27.66M |
| Free cash flow | 781.71M | 530.80M | -87.13700M | -386.42700M | 281.89M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| GIFOF Grifols S.A |
- -% | 8.85 | 12.83 | 9.89 | 0.80 | 0.97 | 1.94 | 8.89 |
| LLY Eli Lilly and Company |
4.79 0.43% | 1111.87 | 78.14 | 31.95 | 16.34 | 45.83 | 16.65 | 54.36 |
| JNJ Johnson & Johnson |
1.44 0.60% | 240.52 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| ABBV AbbVie Inc |
-1.05 0.45% | 233.71 | 86.32 | 14.33 | 5.89 | 50.46 | 7.04 | 24.44 |
| AZN AstraZeneca PLC |
1.86 1.03% | 182.88 | 30.69 | 19.23 | 5.30 | 6.45 | 5.72 | 17.23 |
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Parque Empresarial Can Sant Joan, Barcelona, Spain, 08174
| Name | Title | Year Born |
|---|---|---|
| Mr. Steven Francis Mayer J.D. | Exec. Chairman | 1960 |
| Mr. Raimon Grifols Roura | Co-CEO & Exec. Director | 1964 |
| Mr. Víctor Grifols Deu | Co-CEO & Exec. Director | 1977 |
| Mr. Alfredo Arroyo Guerra | CFO & VP | 1958 |
| Mrs. Eva Bastida Tubau | Corp. VP and Director of Scientific & Medical Affairs | NA |
| Ms. Nuria Pascual Lapeña | VP of Corp. Treasury, Risk Management Investor Relation & Sustainability Officer | 1964 |
| Mr. David Ian Bell | Gen. Counsel & Chief Corp. Devel. Officer | 1954 |
| Mr. Mateo Florencio Borrás Humbert | Corp. VP & Chief HR Officer | 1956 |
| Ms. Maria Teresa-Rioné Llano | Chief Communications Officer | 1965 |
| Ms. Montserrat Gaja Llamas | Chief HR Officer | 1965 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...